Allan J Bigler

Introduction

Allan J Bigler is a distinguished inventor based in Copenhagen, Denmark. He has made significant contributions to the field of pharmaceuticals, particularly through his innovative work on xanthene and thioxanthene derivatives. With a total of five patents to his name, he has focused on creating compounds that offer meaningful pharmacodynamic activity for therapeutic applications.

Latest Patents

Bigler's latest patents include groundbreaking innovations related to novel thioxanthene and xanthene derivatives. These compounds exhibit useful pharmacodynamic activities, such as neuroleptic and antiemetic effects. His inventions also outline methods for the preparation of these derivatives, pharmaceutical compositions that contain them, and therapeutic methods for treating psychic disorders by administering an active amount of these compounds to living organisms, including humans. The new compounds developed under his inventions correspond to a specific chemical formula, which details the varieties of substituents that can be included, such as halogen atoms, alkyl groups, and various functional groups.

Career Highlights

Throughout his career, Allan J Bigler has been committed to pushing the boundaries of pharmaceutical science. His work at Kefalas A/S has been a significant platform for his innovative research. His dedication to improving therapeutic options has led to advances that could enhance the treatment of various psychological conditions.

Collaborations

Allan has collaborated with notable colleagues in his field, including Niels Lassen and Jorn Lasse Buus. These partnerships have facilitated the exchange of innovative ideas and have contributed to the success of his research endeavors.

Conclusion

Allan J Bigler stands out as a successful inventor whose work has the potential to transform therapeutic practices in psychiatry and beyond. His patents not only highlight his ingenuity but also represent a significant contribution to the ongoing development of effective pharmacological treatments. His dedication to innovation continues to inspire future generations of researchers and inventors in the pharmaceutical field.